Claims
- 1. A composition comprising soluble type I collagen, an extracellular matrix protein, and a platelet.
- 2. The composition of claim 1, wherein said composition further comprises plasma.
- 3. The composition of claim 1 or 2, wherein the extracellular matrix protein is selected from the group comprising laminin, fibronectin and entectin.
- 4. The composition of claim 1 or 2, wherein said composition further comprises one or more additives selected from the group comprising insoluble collagen, a growth factor, a cross-linking agent, a stem cell, a genetically altered fibroblast and a cell media supplement.
- 5. The composition of claim 1 or 2, wherein the soluble type I collagen is acid soluble.
- 6. The composition of claim 1 or 2 wherein the soluble type I collagen is basic soluble.
- 7. A composition comprising soluble type I collagen, a platelet and a neutralizing agent.
- 8. The composition of claim 7, wherein said composition further comprises plasma.
- 9. The composition of claim 7, wherein the neutralizing agent is sodium bicarbonate.
- 10. The composition of claim 7 or 8, wherein said composition further comprises one or more additives selected from the group comprising insoluble collagen, an extracellular matrix protein, a growth factor, a cross-linking agent, a stem cell, a genetically altered fibroblast and a cell media supplement.
- 11. A tissue-adhesive composition formulated for administration to a patient, comprising collagen, a neutralizing agent and a platelet.
- 9. The tissue-adhesive composition of claim 8, wherein said platelet is derived from said patient.
- 10. The tissue adhesive composition of claim 8, wherein said composition further comprises plasma.
- 11. The tissue-adhesive composition of claim 10, wherein said plasma is derived from said patient.
- 12. The tissue-adhesive composition of claim 8 wherein said collagen is selected from the group comprising collagen type I, collagen type II, collagen type III, collagen type IV, collagen type V, collagen type IX and collagen type X.
- 13. The tissue-adhesive composition of claim 8, wherein said collagen is acid soluble type I collagen.
- 14. A tissue-adhesive composition formulated for administration to a patient, comprising soluble type I collagen, an extracellular matrix protein, and a platelet derived from said patient.
- 15. The tissue-adhesive composition of claim 3, wherein said composition further comprises plasma derived from said patient.
- 16. A method of treating an intra-articular injury in a subject, the method comprising contacting the ends of a ruptured tissue from the subject with the composition of claim 1 or 7.
- 17. The method of claim 16, wherein the intra-articular injury is a meniscal tear, ligament tear or a cartilage lesion.
- 18. The method of claim 16, further comprising mechanically joining the ends of the ruptured tissue.
- 19. A method of treating an extra-articular injury in a subject, the method comprising contacting the ends of a ruptured tissue from the subject with the composition of claim 1 or 7.
- 20. The method of claim 16, wherein the extra-articular injury is ligament, tendon or muscle injury.
- 21. The method of claim 16, further comprising mechanically joining the ends of the ruptured tissue.
CLAIM OF PRIORITY
[0001] This application is a continuation of U.S. application Ser. No. 09/594,295 filed Jun. 15, 2000 which claims priority to U.S. patent applications No. 60/140,197, filed Jun. 22, 1999, and No. 60/182,972, filed Feb. 16, 2000.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60140197 |
Jun 1999 |
US |
|
60182972 |
Feb 2000 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09594295 |
Jun 2000 |
US |
Child |
09917058 |
Jul 2001 |
US |